JY
TARS icon

Jeff Yass’s Tarsus Pharmaceuticals TARS Stock Holding History

Jeff Yass’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9M Buy
188,500
+153,900
+445% +$9.83M ﹤0.01% 3116
2026
Q1 		$2.43M Buy
34,600
+5,100
+17% +$356K ﹤0.01% 5725
2025
Q4 		$2.42M Buy
29,500
+11,800
+67% +$881K ﹤0.01% 5249
2025
Q3 		$1.05M Buy
+17,700
New +$871K ﹤0.01% 7244
2025
Q2 		– Sell
-5,300
Closed -$272K – 13699
2025
Q1 		$272K Sell
5,300
-13,100
-71% -$648K ﹤0.01% 10264
2024
Q4 		$1.02M Sell
18,400
-9,200
-33% -$418K ﹤0.01% 6895
2024
Q3 		$908K Sell
27,600
-3,400
-11% -$95.6K ﹤0.01% 7005
2024
Q2 		$843K Buy
31,000
+5,700
+23% +$192K ﹤0.01% 6992
2024
Q1 		$920K Buy
+25,300
New +$744K ﹤0.01% 7105
2023
Q4 		– Sell
-19,100
Closed -$339K – 13274
2023
Q3 		$339K Buy
19,100
+3,600
+23% +$63.7K ﹤0.01% 9094
2023
Q2 		$280K Buy
+15,500
New +$246K ﹤0.01% 9579
2022
Q4 		– Sell
-26,300
Closed -$450K – 13639
2022
Q3 		$450K Sell
26,300
-1,100
-4% -$17.5K ﹤0.01% 8770
2022
Q2 		$400K Buy
+27,400
New +$411K ﹤0.01% 8811

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jeff Yass's TARS Position: Q2 2026 in Review

Jeff Yass increased its Tarsus Pharmaceuticals (TARS) stake by 100% in Q2 2026, buying an estimated $1.06M and bringing the position to 33,290 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #6383.

Jeff Yass first reported a position in TARS in Q3 2022 and has held it in 11 quarters since. The position peaked at $3.55M in Q4 2024. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Jeff Yass held 33,290 shares of Tarsus Pharmaceuticals worth $2.1M as of Q2 2026.
  • Jeff Yass bought 16,655 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.06M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6383 holding.
  • Jeff Yass first reported a position in Tarsus Pharmaceuticals in Q3 2022 and has held it in 11 quarters since.
  • Jeff Yass's Tarsus Pharmaceuticals position peaked at $3.55M in Q4 2024.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.